# Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)

> **NCT06967753** · PHASE4 · RECRUITING · sponsor: **UBATEC** · enrollment: 50 (estimated)

## Conditions studied

- HIV
- HIV-1

## Interventions

- **DRUG:** Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)

## Key facts

- **NCT ID:** NCT06967753
- **Lead sponsor:** UBATEC
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-31
- **Primary completion:** 2026-12
- **Final completion:** 2027-02
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-09-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06967753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06967753, "Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06967753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*